(TXG) 10X Genomics - Overview
Stock: Chromium, Visium, Xenium, Consumables, Software
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 67.7% |
| Relative Tail Risk | -7.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.63 |
| Alpha | 0.32 |
| Character TTM | |
|---|---|
| Beta | 1.921 |
| Beta Downside | 1.596 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.66% |
| CAGR/Max DD | -0.28 |
Description: TXG 10X Genomics January 15, 2026
10x Genomics (NASDAQ:TXG) is a U.S.-based life-science technology firm that designs, manufactures, and sells integrated hardware, consumables, and analysis software for high-throughput single-cell and spatial genomics across the Americas, EMEA, China, and APAC.
The company’s flagship Chromium platform delivers single-cell and single-nucleus profiling via microfluidic chips and the Chromium X Series instruments, while the Visium platform provides spatial gene-expression mapping (including HD and protein-expression assays) with the Visium CytAssist to streamline slide-to-slide transfers. Its Xenium Analyzer adds multiplexed RNA-in-situ detection on fresh-frozen or FFPE tissue sections.
Customers span academic research labs, government institutes, and biopharma/biotech companies that require high-resolution molecular profiling for drug target discovery, biomarker development, and functional genomics.
Key recent metrics: FY 2023 revenue reached approximately $1.5 billion, up ~30 % YoY, driven by a 45 % increase in Chromium consumable sales; gross margin held steady near 78 %; and the company’s cash balance exceeded $1 billion, supporting ongoing R&D and capacity expansion. The single-cell sequencing market is projected to grow at a ~20 % CAGR through 2030, providing a strong secular tailwind for 10x’s product suite.
For a deeper dive into how 10x Genomics’ valuation compares to sector peers, you might explore the analytical tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -76.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 5.28 > 1.0 |
| NWC/Revenue: 79.85% < 20% (prev 75.06%; Δ 4.80% < -1%) |
| CFO/TA 0.09 > 3% & CFO 88.5m > Net Income -76.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (125.5m) vs 12m ago 3.95% < -2% |
| Gross Margin: 68.83% > 18% (prev 0.67%; Δ 6817 % > 0.5%) |
| Asset Turnover: 65.32% > 50% (prev 67.15%; Δ -1.83% > 0%) |
| Interest Coverage Ratio: -5221 > 6 (EBITDA TTM -30.8m / Interest Expense TTM 14.0k) |
Altman Z'' -8.48
| A: 0.50 (Total Current Assets 659.8m - Total Current Liabilities 147.3m) / Total Assets 1.03b |
| B: -1.45 (Retained Earnings -1.49b / Total Assets 1.03b) |
| C: -0.07 (EBIT TTM -73.1m / Avg Total Assets 982.6m) |
| D: -6.20 (Book Value of Equity -1.49b / Total Liabilities 241.0m) |
| Altman-Z'' Score: -8.48 = D |
Beneish M -2.18
| DSRI: 1.13 (Receivables 96.6m/83.5m, Revenue 641.8m/629.7m) |
| GMI: 0.97 (GM 68.83% / 66.58%) |
| AQI: 2.55 (AQ_t 0.07 / AQ_t-1 0.03) |
| SGI: 1.02 (Revenue 641.8m / 629.7m) |
| TATA: -0.16 (NI -76.3m - CFO 88.5m) / TA 1.03b) |
| Beneish M-Score: -2.18 (Cap -4..+1) = BB |
What is the price of TXG shares?
Over the past week, the price has changed by -7.87%, over one month by -3.63%, over three months by +43.15% and over the past year by +27.03%.
Is TXG a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TXG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.1 | -2.8% |
| Analysts Target Price | 18.1 | -2.8% |
| ValueRay Target Price | 18.2 | -2.4% |
TXG Fundamental Data Overview February 05, 2026
P/S = 3.8016
P/B = 3.2157
Revenue TTM = 641.8m USD
EBIT TTM = -73.1m USD
EBITDA TTM = -30.8m USD
Long Term Debt = 87.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.5m USD (from shortTermDebt, last quarter)
Debt = 87.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -345.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.04b USD (2.44b + Debt 87.0m - CCE 482.1m)
Interest Coverage Ratio = -5221 (Ebit TTM -73.1m / Interest Expense TTM 14.0k)
EV/FCF = 25.04x (Enterprise Value 2.04b / FCF TTM 81.7m)
FCF Yield = 3.99% (FCF TTM 81.7m / Enterprise Value 2.04b)
FCF Margin = 12.72% (FCF TTM 81.7m / Revenue TTM 641.8m)
Net Margin = -11.89% (Net Income TTM -76.3m / Revenue TTM 641.8m)
Gross Margin = 68.83% ((Revenue TTM 641.8m - Cost of Revenue TTM 200.0m) / Revenue TTM)
Gross Margin QoQ = 67.32% (prev 72.34%)
Tobins Q-Ratio = 1.99 (Enterprise Value 2.04b / Total Assets 1.03b)
Interest Expense / Debt = 0.00% (Interest Expense 3000 / Debt 87.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -57.7m (EBIT -73.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.48 (Total Current Assets 659.8m / Total Current Liabilities 147.3m)
Debt / Equity = 0.11 (Debt 87.0m / totalStockholderEquity, last quarter 785.1m)
Debt / EBITDA = 11.22 (negative EBITDA) (Net Debt -345.5m / EBITDA -30.8m)
Debt / FCF = -4.23 (Net Debt -345.5m / FCF TTM 81.7m)
Total Stockholder Equity = 743.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -7.77% (Net Income -76.3m / Total Assets 1.03b)
RoE = -10.26% (Net Income TTM -76.3m / Total Stockholder Equity 743.9m)
RoCE = -8.80% (EBIT -73.1m / Capital Employed (Equity 743.9m + L.T.Debt 87.0m))
RoIC = -7.76% (negative operating profit) (NOPAT -57.7m / Invested Capital 743.9m)
WACC = 12.54% (E(2.44b)/V(2.53b) * Re(12.99%) + D(87.0m)/V(2.53b) * Rd(0.00%) * (1-Tc(0.21)))
Discount Rate = 12.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.88%
[DCF Debug] Terminal Value 52.84% ; FCFF base≈59.0m ; Y1≈38.7m ; Y5≈17.7m
Fair Price DCF = 4.66 (EV 197.7m - Net Debt -345.5m = Equity 543.2m / Shares 116.5m; r=12.54% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 65.56 | EPS CAGR: 17.91% | SUE: 1.05 | # QB: 1
Revenue Correlation: 64.36 | Revenue CAGR: 1.00% | SUE: 0.53 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.17 | Chg30d=+0.005 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.39 | Chg30d=+0.023 | Revisions Net=+0 | Growth EPS=-1349.8% | Growth Revenue=-4.4%